MLchartDataset catalogue

anti-PSMA/CD3 bispecific antibody CCW702

Term · Oncology and biomedicine · MLC-T-ONC-011056

A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-PSMA/CD3 bispecific antibody CCW702, this bispecific antibody binds to both CD3 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.

Table 1. Record
IdentifierMLC-T-ONC-011056
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011056",
  "term": "anti-PSMA/CD3 bispecific antibody CCW702",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-PSMA/CD3 bispecific antibody CCW702, this bispecific antibody binds to both CD3 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-psma-cd3-bispecific-antibody-ccw702/"
}

Record 2,187 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.